Genmab A/S

NASDAQ:GMABUnited States

Genmab A/S is a Denmark-based international biotechnology company. It specializes in the creation and development of antibody therapeutics for the treatment of cancer. The Company is the creator of the approved antibodies: DARZALEX (daratumumab) for the treatment of certain multiple myeloma indications, Kesimpta for the treatment of adults with relapsing forms of multiple sclerosis, TEPEZZA (teprotumumab) for the treatment of thyroid eye disease and FASPRO, for the treatment of adult patients with certain multiple myeloma indications. The first approved Genmab created therapy Arzerra, approved for the treatment of certain chronic lymphocytic leukemia indications, is available in Japan and is also available in other territories via compassionate use or oncology access programs. Genmab develops a broad clinical and pre-clinical product pipeline, and owns four antibody technologies, DuoBody bispecific platform, HexaBody platform, DuoHexaBody platform & HexElect platform.

Contact Information

Headquarters

Carl Jacobsens Vej 30VALBY, Denmark 2500

Phone

---

Fax

---

Executives

Independent Chairman of the Board

Deirdre Connelly

President, Chief Executive Officer

Jan Van De Winkel

Independent Deputy Chairman of the Board

Pernille Erenbjerg

Chief Financial Officer, Executive Vice President

Anthony Pagano

Executive Vice President, Chief People Officer

Christopher Cozic